For men with localized intermediate-risk prostate cancer, a high-tech radiation treatment that can complete therapy in just a few sessions did not outperform a more conventional abbreviated radiation approach in controlling the disease, according to a randomized clinical trial of 698 patients published in JAMA. The study compared stereotactic body radiotherapy, commonly known as SBRT, with moderately hypofractionated intensity-modulated radiation therapy, or IMRT. Although SBRT offered an advantage in bowel-related quality of life, the trial found no evidence that it improved disease-free survival at three years.
The findings address a question that has become increasingly important as radiation oncology moves toward shorter, more precisely targeted treatment schedules. Traditional prostate radiotherapy may require many weeks of daily sessions, while both moderately hypofractionated IMRT and SBRT deliver larger doses during each visit, reducing the overall number of treatments. SBRT pushes this concept further by concentrating radiation into a small number of highly focused sessions. The approach is designed to exploit the physical precision of modern imaging and treatment systems while limiting exposure to nearby healthy tissue, particularly the bladder and rectum.
In the trial, patients had prostate cancer classified as localized and intermediate risk, meaning the disease had not spread beyond the prostate but had biological or pathological features associated with a meaningful risk of recurrence. Participants were randomly assigned to receive either SBRT or moderately hypofractionated IMRT. Randomization is a key feature of comparative clinical research because it helps distribute known and unknown risk factors between treatment groups, making it less likely that differences in outcomes are caused by variations in patient selection rather than by the treatments themselves.
The primary question was whether SBRT could provide superior disease-free survival at three years. Disease-free survival is a composite measure that generally captures the length of time patients remain free from evidence of cancer recurrence, progression, or other predefined treatment failure events. In localized prostate cancer, recurrence may be detected through rising prostate-specific antigen levels, clinical evidence of returning disease, the need for additional treatment, or the appearance of metastases, depending on the study’s formal definitions. In this trial, SBRT did not meet the standard for superiority over moderately hypofractionated IMRT.
That result does not mean the two strategies are identical in every respect, nor does it suggest that SBRT is ineffective. Rather, it indicates that the shorter, more concentrated treatment did not produce better cancer-control outcomes during the three-year evaluation period. For patients and clinicians, the distinction is important. A treatment can be considered a reasonable alternative because it achieves comparable outcomes, even when it fails to demonstrate superiority. The trial’s findings therefore place SBRT within a discussion about convenience, side effects, access, and patient preference rather than presenting it as a treatment that eliminates the risk of recurrence more effectively.
SBRT uses advanced planning and image guidance to deliver large radiation doses to the prostate while attempting to spare surrounding organs. The biological effect of radiation depends not only on the total dose but also on the dose delivered during each fraction. Because prostate cancer cells and nearby normal tissues may respond differently to changes in fraction size, researchers have studied whether larger individual doses could produce a therapeutic advantage. At the same time, the prostate lies close to the rectum, bladder, urethra, and sexual organs, so even small uncertainties in organ position or movement can influence toxicity. These technical considerations make precision, immobilization, and real-time or repeated imaging central to SBRT.
Moderately hypofractionated IMRT also represents a modern form of precision radiation therapy. It uses computer-controlled beams that vary in intensity and shape as they enter the body, allowing clinicians to conform the radiation dose to the prostate and reduce exposure to adjacent structures. The treatment is delivered over more sessions than SBRT, but still fewer than older conventional schedules. Because both approaches use contemporary planning methods and shortened treatment courses, the comparison is not between experimental technology and outdated therapy. Instead, it evaluates two increasingly common strategies within the same broader shift toward efficient, image-guided radiation treatment.
The trial did identify a quality-of-life difference: patients receiving SBRT reported better bowel-related quality of life. Bowel symptoms after prostate radiotherapy can include urgency, increased frequency, loose stools, rectal discomfort, bleeding, or changes in bowel control. Such effects may result from incidental radiation exposure to the rectum and lower bowel, even when treatment is carefully planned. Patient-reported outcomes are especially valuable in this setting because physician assessments may not fully capture symptoms that affect daily activities, social confidence, and long-term well-being. The bowel-related advantage associated with SBRT suggests that fewer treatment sessions or differences in dose distribution may have practical consequences beyond the central cancer outcome.
However, the quality-of-life finding must be interpreted alongside the absence of improved disease-free survival. A treatment decision involves balancing tumor control against side effects, inconvenience, cost, travel requirements, and the patient’s medical circumstances. SBRT may be attractive to people who live far from a treatment center, have difficulty attending repeated appointments, or prioritize a shorter course. Other patients may have anatomical, urinary, bowel, or technical factors that influence which approach is most appropriate. The trial does not establish that one radiation schedule should replace the other for every person, but it provides evidence that a shorter course should not automatically be promoted as a superior cancer treatment.
The study was led by Rodney J. Ellis, MD, of the University of South Florida, and was published in JAMA. Its results contribute to a growing body of evidence examining how far radiation therapy can be compressed without compromising long-term control of prostate cancer. The three-year endpoint is clinically meaningful, but prostate cancer can recur many years after initial treatment, so longer follow-up will be essential. Future analyses may clarify whether the early equivalence between SBRT and moderately hypofractionated IMRT persists over time, whether specific patient subgroups benefit more from one approach, and how urinary, sexual, and bowel outcomes evolve in the years after treatment. For now, the trial’s central message is measured but consequential: SBRT offers a shorter treatment pathway and was associated with better bowel-related quality of life, yet it did not improve three-year disease-free survival compared with moderately hypofractionated IMRT.
Subject of Research: Stereotactic body radiotherapy versus moderately hypofractionated intensity-modulated radiation therapy for localized intermediate-risk prostate cancer.
Web References: https://doi.org/10.1001/jama.2026.12627
References: JAMA randomized clinical trial of 698 patients with localized intermediate-risk prostate cancer; DOI: 10.1001/jama.2026.12627.
Keywords: Prostate cancer, stereotactic body radiotherapy, SBRT, moderately hypofractionated IMRT, radiation therapy, disease-free survival, bowel-related quality of life, oncology, cancer treatment.
